articleThe LancetSep 1, 2020Closed access

Lisocabtagene maraleucel for patients with relapsed or refractory large B-cell lymphomas (TRANSCEND NHL 001): a multicentre seamless design study

JSJeremy S AbramsonMLM. Lia PalombaLILeo I. GordonMAMatthew A. LunningMWMichael Wang

Massachusetts General Hospital · Memorial Sloan Kettering Cancer Center · +15 more institutions

PubMed
Indexed incrossrefpubmed

Abstract

No abstract available for this paper.

Citation impact

2,299
total citations
FWCI
105.49
Percentile
100%
References
44
Citations per year

Authors

22

Topics & keywords

Keywords
  • Refractory (planetary science)
  • Medicine
  • Internal medicine
  • Oncology
  • Lymphoma
  • Biology
UN Sustainable Development Goals
  • Life below water
No related works found for this paper.

Funding